Adma Biologics

(NASDAQ) ADMA

Current Price$10.61

Market Cap$2.53B

Since IPO (2013)+28%

5 Year+432%

1 Year-56%

1 Month+18%

Adma Biologics Financials at a Glance

Market Cap

$2.53B

Revenue (TTM)

$510.17M

Net Income (TTM)

$146.93M

EPS (TTM)

$0.60

P/E Ratio

18.20

Dividend

$0.00

Beta (Volatility)

1.22 (Average)

Dividend

$0.00

Beta (Volatility)

1.22 (Average)

Price

$10.61

Volume

225,178

Open

$10.76

Price

$10.61

Volume

225,178

Open

$10.76

Previous Close

$10.61

Daily Range

$10.42 - $10.76

52-Week Range

$7.21 - $24.19

Dividend

$0.00

Beta (Volatility)

1.22 (Average)

Price

$10.61

Volume

225,178

Open

$10.76

Previous Close

$10.61

Daily Range

$10.42 - $10.76

52-Week Range

$7.21 - $24.19

ADMA News

What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump

Keith SpeightsAug 25, 2020

Page 1

ADMA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adma Biologics

Industry

Biotechnology

Sector

Health Care

Employees

647

CEO

Adam S. Grossman

Website

www.admabiologics.com

Headquarters

Ramsey, NJ 07446, US

ADMA Financials

Key Financial Metrics (TTM)

Gross Margin

57%

Operating Margin

38%

Net Income Margin

29%

Return on Equity

36%

Return on Capital

35%

Return on Assets

24%

Earnings Yield

5.49%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.53B

Shares Outstanding

232.32M

Volume

225.18K

Avg. Volume

5.85M

Financials (TTM)

Gross Profit

$292.76M

Operating Income

$191.44M

EBITDA

$197.86M

Operating Cash Flow

$50.40M

Capital Expenditure

$22.57M

Free Cash Flow

$27.82M

Cash & ST Invst.

$87.63M

Total Debt

$79.89M

Adma Biologics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$139.16M

+18.4%

Gross Profit

$88.82M

+40.2%

Gross Margin

63.82%

N/A

Market Cap

$2.53B

N/A

Market Cap/Employee

$3.70M

N/A

Employees

685

N/A

Net Income

$49.38M

-55.9%

EBITDA

$65.27M

+65.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$7.75M

-63.2%

Accounts Receivable

$158.43M

+216.9%

Inventory

$206.47M

+21.3%

Long Term Debt

$75.98M

-6.1%

Short Term Debt

$3.91M

+220.9%

Return on Assets

23.54%

N/A

Return on Invested Capital

34.51%

N/A

Free Cash Flow

$34.55M

-27.2%

Operating Cash Flow

$35.64M

-29.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

RAREUltragenyx Pharmaceutical Inc.

RAREUltragenyx Pharmaceutical Inc.$24.18-1.43%

SLNOSoleno Therapeutics, Inc.

SLNOSoleno Therapeutics, Inc.$52.78+0.04%

DYNDyne Therapeutics, Inc.

DYNDyne Therapeutics, Inc.$17.41-4.13%

TLXTelix Pharmaceuticals Limited

TLXTelix Pharmaceuticals Limited$10.43-0.10%

ACADACADIA Pharmaceuticals Inc.

ACADACADIA Pharmaceuticals Inc.$22.20-2.07%

CRNXCrinetics Pharmaceuticals, Inc.

CRNXCrinetics Pharmaceuticals, Inc.$38.44+0.76%

LGNDLigand Pharmaceuticals Incorporated

LGNDLigand Pharmaceuticals Incorporated$224.86-3.21%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$94.75+0.12%

SOFISoFi Technologies

SOFISoFi Technologies$15.53-0.15%

NOKNokia

NOKNokia$12.46+0.10%

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.14+0.04%

HOODRobinhood Markets

HOODRobinhood Markets$71.20-0.13%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$61.86+0.02%

POETPoet Technologies

POETPoet Technologies$6.60-0.18%

Questions About ADMA

What is the current price of Adma Biologics?

Adma Biologics is trading at $10.61 per share.

What is the 52-week range for Adma Biologics?

Over the past 52 weeks, Adma Biologics has traded between $7.21 and $24.19.

How much debt does Adma Biologics have?

As of the most recent reporting period, Adma Biologics reported total debt of $79.89M.

How much cash does Adma Biologics have on hand?

Adma Biologics reported $87.63M in cash and cash equivalents in its most recent financial results.

What is Adma Biologics’s dividend yield?

Adma Biologics does not currently have a dividend yield.

Adma Biologics

Adma Biologics Financials at a Glance

ADMA News

This Small-Cap Fund Just Dumped $7 Million in ADMA Stock — Here’s Why

Adma Biologics (ADMA) Q2 Revenue Up 14%

Why Adma Biologics Stock Crushed the Market on Friday

Why Adma Biologics Was Trouncing the Market Today

Why Shares of ADMA Biologics Are Climbing Thursday

Why ADMA Biologics Stock Triumphed on Thursday

Is ADMA Biologics a Good Coronavirus Stock to Buy Now?

What You Need to Know About the "Breakthrough" Coronavirus Therapy Heralded by President Trump

ADMA: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Adma Biologics

ADMA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Adma Biologics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ADMA

What is the current price of Adma Biologics?

What is the 52-week range for Adma Biologics?

How much debt does Adma Biologics have?

How much cash does Adma Biologics have on hand?

What is Adma Biologics’s dividend yield?

Premium Investing Services